Evidence map›Paper›PMID 40365406›Full record

ArticleACS medicinal chemistry letters2025

PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational Medicine.

Taoqian Zhao, Steven H Liang

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Taoqian ZhaoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.ORCID https://orcid.org/0000-0003-1413-6315

Funding

Subtype-selective phosphodiesterase PET ligandsR01AG079956 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2023 to 2025
$2.3M
PET imaging for neuroimmune function in Alzheimer's diseaseR21AG078058 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2022 to 2022
$430k
NIA NIH HHS R01 AG079956NIA NIH HHS R21 AG078058
6 · The paper itself

Abstract

Phosphodiesterase 7 (PDE7) regulates cAMP-PKA signaling and plays a crucial role in immune function, neuroprotection, and inflammation. Dysregulated PDE7 activity is linked to neurodegenerative, autoimmune, and metabolic disorders, making it a promising therapeutic target. Recent advancements in PDE7 inhibitors, particularly pyrimidinone-based compounds, have shown high selectivity and potent biological effects. Beyond therapeutics, radiolabeled PDE7 inhibitors offer potential for PET imaging, enabling noninvasive disease monitoring and treatment assessment.

Identifiers

PMID40365406
PMCPMC12067116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.